Citations

Clear

941 citation(s) found for "Tefferi, A".

Response: Factors considered in the 2008 WHO classification of myeloid neoplasms and acute leukemias
Vardiman, James W., Thiele, Jürgen, Brunning, Richard D., Borowitz, Michael J., Beau, Michelle M. Le , Hellström‐Lindberg, Eva , Tefferi, Ayalew , Bloomfield, Clara D. , Arber, Daniel A. , Porwit, Anna , Harris, Nancy L.

Mayo Clinic

Blood | January 21, 2010 | Volume: 115 | Issue: 3 | Pages: 749-750

10.1182/blood-2009-11-250399 Get It

Response: Capturing variables with prognostic relevance in development of a new scoring system for primary myelofibrosis
Cervantes, Francisco , Pereira, Arturo , Tefferi, Ayalew

Mayo Clinic

Blood | January 21, 2010 | Volume: 115 | Issue: 3 | Pages: 745-746

10.1182/blood-2009-10-248013 Get It

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome–negative myeloproliferative neoplasms
Thoennissen, Nils H., Krug, Utz , Lee, Dhong Hyun Tony, Kawamata, Norihiko , Iwanski, Gabriela B., Weiss, Tamara, Nowak, Daniel , Koren‐Michowitz, Maya , Kato, Motohiro , Sanada, Masashi , Nagler, Arnon , Raynaud, Sophie , Müller‐Tidow, Carsten , Haferlach, Torsten , Gilliland, D. Gary, Tefferi, Ayalew , Koeffler, H. Phillip , Lasho, Terra L. , Shih, Lee‐Yung , Mesa, Ruben A. , Ogawa, Seishi , Kato, Motohiro

Mayo Clinic

Blood | January 13, 2010 | Volume: 115 | Issue: 14 | Pages: 2882-2890

10.1182/blood-2009-07-235119 | PMID 20068225 Get It

Abstract Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and primary myelofibrosis show an inherent tendency for transformation into leukemia (MPN-blast phase), which is hypothesized to be accompanied by acquisition of additional genomic lesions. We, therefore, examined chromosomal abnormalities by high-resolution single nucleotide polymorphism (SNP) array in 88 MPN patients, as well as 71 cases with MPN-blast phase, and correlated these findings with their clinical parameters. Frequent genomic alterations were found in MPN after leukemic transformation with up to 3-fold more genomic changes per sample compared with samples in chronic phase (P < .001). We identified commonly altered regions involved in disease progression including not only established targets (ETV6, TP53, and RUNX1) but also new candidate genes on 7q, 16q, 19p, and 21q. Moreover, trisomy 8 or amplification of 8q24 (MYC) was almost exclusively detected in JAK2V617F− cases with MPN-blast phase. Remarkably, copy number–neutral loss of heterozygosity (CNN-LOH) on either 7q or 9p including homozygous JAK2V617F was related to decreased survival after leukemic transformation (P = .01 and P = .016, respectively). Our high-density SNP-array analysis of MPN genomes in the chronic compared with leukemic stage identified novel target genes and provided prognostic insights associated with the evolution to leukemia.
WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults
Pardanani, Animesh , Finke, Christy M. , McClure, Rebecca F., Li, Chin‐Yang, Tefferi, Ayalew , Lim, Ken‐Hong , Lasho, Terra L. , Li, Chin‐Yang

Mayo Clinic

Blood | January 7, 2010 | Volume: 115 | Issue: 1 | Pages: 150-151

10.1182/blood-2009-10-249979 | PMID 20056798 Get It

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Passamonti, Francesco , Cervantes, Francisco , Morra, Enrica, Rumi, Elisa , Pereira, Arturo , Guglielmelli, Paola , Pungolino, Ester , Caramella, Marianna, Maffioli, Margherita , Pascutto, Cristiana, Lazzarino, Mario, Cazzola, Mario , Tefferi, Ayalew , Vannucchi, Alessandro M. , Passamonti, Francesco , Cazzola, Mario , Guglielmelli, Paola

Mayo Clinic

Blood | December 14, 2009 | Volume: 115 | Issue: 9 | Pages: 1703-1708

10.1182/blood-2009-09-245837 | PMID 20008785 Get It

Abstract Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count greater than 25 × 109/L, peripheral blood blasts 1% or higher, and constitutional symptoms have been shown to predict poor survival in primary myelofibrosis (PMF) at diagnosis. To investigate whether the acquisition of these factors during follow-up predicts survival, we studied 525 PMF patients regularly followed. All 5 variables had a significant impact on survival when analyzed as time-dependent covariates in a multivariate Cox proportional hazard model and were included in 2 separate models, 1 for all patients (Dynamic International Prognostic Scoring System [DIPSS]) and 1 for patients younger than 65 years (age-adjusted DIPSS). Risk factors were assigned score values based on hazard ratios (HRs). Risk categories were low, intermediate-1, intermediate-2, and high in both models. Survival was estimated by the HR. When shifting to the next risk category, the HR was 4.13 for low risk, 4.61 for intermediate-1, and 2.54 for intermediate-2 according to DIPSS; 3.97 for low risk, 2.84 for intermediate-1, and 1.81 for intermediate-2 according to the age-adjusted DIPSS. The novelty of these models is the prognostic assessment of patients with PMF anytime during their clinical course, which may be useful for treatment decision-making.
International Prognostic Scoring System–independent cytogenetic risk categorization in primary myelofibrosis
Hussein, Kebede, Pardanani, Animesh , Dyke, Daniel L. Van , Hanson, Curtis A. , Tefferi, Ayalew

Mayo Clinic

Blood | November 10, 2009 | Volume: 115 | Issue: 3 | Pages: 496-499

10.1182/blood-2009-08-240135 | PMID 19901264 Get It

Abstract Among 200 patients with primary myelofibrosis, karyotype at diagnosis was abnormal in 83 (42%). To assess their individual prognostic impact, specific cytogenetic abnormalities with more than or equal to 5 informative cases were identified and the rest grouped separately as “other abnormalities.” Median survival in patients with sole +9 (n = 6), sole 20q− (n = 21), sole 13q− (n = 8), normal karyotype (n = 117), “other abnormalities” (n = 28), complex karyotype (n = 13), and sole +8 (n = 7) were “not reached,” 112, 105, 80, 46, 34, and 28 months, respectively (P = .01). Accordingly, 4 cytogenetic risk groups were considered: (1) favorable (sole +9, 20q−, or 13q−), (2) normal, (3) unfavorable (complex karyotype or sole +8), and (4) “other abnormalities.” Multivariable analysis confirmed the International Prognostic Scoring System (IPSS)–independent prognostic value of both 4-way and 2-way (ie, favorable/normal vs unfavorable/other abnormalities; IPSS-adjusted hazard ratio = 0.37; 95% confidence interval, 0.24-0.58) cytogenetic risk categorization (P < .01). The ability to prognostically dissect a specific IPSS category has major therapeutic implications.
Bone Marrow Fibrosis and Diagnosis of Essential Thrombocythemia
Thiele, Jüergen, Kvasnicka, Hans Michael , Vardiman, James W., Orazi, Attilio , Gisslinger, Heinz , Birgegård, Gunnar , Grießhammer, Martin , Tefferi, Ayalew , Franco, Vito , Orazi, Attilio

Mayo Clinic

Journal of Clinical Oncology | October 27, 2009 | Volume: 27 | Issue: 34 | Pages: e220-e221

10.1200/jco.2009.24.3485 | PMID 19858378 Get It

Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis
Pardanani, Animesh , Tefferi, Ayalew , Litzow, Mark R. , McClure, Rebecca F., Viswanatha, David S., Zent, Clive S. , Hogan, William J.

Mayo Clinic

Blood | October 15, 2009 | Volume: 114 | Issue: 16 | Pages: 3502-3503

10.1182/blood-2009-07-234666 | PMID 19833856 Get It

Chronic natural killer–cell lymphocytosis successfully treated with alemtuzumab
Warrington, Kenneth J. , Tefferi, Ayalew , Chee, Cheng Ean , Warrington, Kenneth J

Mayo Clinic

Blood | October 15, 2009 | Volume: 114 | Issue: 16 | Pages: 3500-3502

10.1182/blood-2009-07-233403 | PMID 19833855 Get It

Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies
Pardanani, Animesh , Finke, Christy M. , McClure, Rebecca F., Li, Chin‐Yang, Tefferi, Ayalew , Lim, Ken‐Hong , Lasho, Terra L. , Li, Chin‐Yang

Mayo Clinic

Blood | August 28, 2009 | Volume: 114 | Issue: 18 | Pages: 3769-3772

10.1182/blood-2009-05-220145 | PMID 19713463 Get It

Abstract The prognostic heterogeneity of the World Health Organization category of “systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease” (SM-AHNMD) has not been systematically validated by primary data. Among 138 consecutive cases with SM-AHNMD, 123 (89%) had associated myeloid neoplasm: 55 (45%) myeloproliferative neoplasm (SM-MPN), 36 (29%) chronic myelomonocytic leukemia, 28 (23%) myelodysplastic syndrome (SM-MDS), and 4 (3%) acute leukemia. Of the myeloid subgroups, SM-MPN displayed a 2- to 3-fold better life expectancy (P = .003), whereas leukemic transformation was more frequent in SM-MDS (29%; P = .02). The presence of eosinophilia, although prevalent (34%), was prognostically neutral, and the overall results were not affected by exclusion of FIP1L1-PDGFRA-positive cases. We conclude that it is clinically more useful to consider specific entities, such as SM-MPN, systemic mastocytosis with chronic myelomonocytic leukemia, SM-MDS, and systemic mastocytosis with-acute leukemia, rather than their broad reference as SM-AHNMD.